Bayer to discontinue the LIPLONG study Bayer Schering Pharma AG.

Bayer to discontinue the LIPLONG study Bayer Schering Pharma AG, Germany has announced an independent Data Security and Monitoring Plank offers completed an interim evaluation of a stage II trial of the business’s long-acting recombinant aspect VIII, BAY79-4980. The DSMB figured the study will never be able to obtain the predetermined efficacy endpoint . No basic safety concerns were raised is caverta as effective as viagra click here . As a complete consequence of the DSMB results and recommendation, Bayer has made a decision to discontinue the study. While we are disappointed with the results of the evaluation, we remain focused on developing our long-performing recombinant element VIII compounds, stated Kemal Malik, M.D., person in the Board of Administration of Bayer Schering Pharma AG and Mind of Global Development.